Description：Rabbit polyclonal antibody to mTORImmunogen：KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human mTOR. The exact sequence is proprietary.Purification：The antibody was purified by immunogen affinity chromatography.Clonality：PolyclonalForm：Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.Dilution：WB (1/500 - 1/1000), IH (1/100 - 1/200)Gene Symbol：MTORAlternative Names：FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic target of rapamycin; Rapamycin and FKBP12 target 1; Rapamycin target protein 1 Entrez Gene (Human)： 2475; Entrez Gene (Mouse)： 56717; Entrez Gene (Rat)： 56718; SwissProt (Human)： P42345; SwissProt (Mouse)： Q9JLN9; SwissProt (Rat)： P42346; Storage/Stability：Shipped at 4°C. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles.

• 
  Western blot analysis of mTOR expression in HEK293T (A), NIH3T3 (B) whole cell lysates. (Predicted band size: 288 kD; Observed band size: 289 kD)
• 
  Immunohistochemical analysis of mTOR staining in human prostate cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.